ReviewCirculation research2023
Platelets and SARS-CoV-2 During COVID-19: Immunity, Thrombosis, and Beyond.
Review in Circulation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 54 citations in OpenAlex.
- Long-term impact of COVID-19 on haemophilia: a multicenter study in Southwest China.BMC infectious diseases · 2026Article
- Association of Fibrinogen Beta Chain (FGB) rs1800790 and ITGB3 rs5918 gene variants with coagulation and ınflammation parameters according to sex in COVID-19 patients.Journal of thrombosis and thrombolysis · 2026Article
- Megakaryocytes Internalize and Are Activated by Immune Complexes.Circulation research · 2026Article
- A Post-GWAS Analysis of the Shared Genetic Architecture Between COVID-19 and Coronary Artery Disease.International journal of molecular sciences · 2026Article
- Associations of blood donor and product characteristics with platelet transfusion outcomes.Blood advances · 2026Article
- Platelet Count and Platelet Indices as Predictive Markers of COVID-19 Mortality.Physiological research · 2026Article
- The Platelet-Virus Axis in Human Disease.Viruses · 2026Review
- Article
- Platelet-derived mediators in hospitalized COVID-19 patients and associations to respiratory failure, ICU admittance and 60-day mortality.Frontiers in cardiovascular medicine · 2026Article
- Mean platelet volume and long-term cardiovascular outcomes in patients with type 2 diabetes mellitus.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Expression Levels of PF4, ALOX12, ITGA2B, F131A in Pregnant COVID-19 Survivors.Biochemical genetics · 2025Article
- A Retrospective Multicenter Study of Arterial Thromboembolic Events in Hospitalized COVID-19 Patients: Incidence and Imaging Characteristics.Clinical neuroradiology · 2025Article
- Pattern recognition receptor-associated immuno-thrombotic transcript changes in platelets and leukocytes with COVID19.PLoS pathogens · 2025Article
- Hematologic and Immunologic Overlap Between COVID-19 and Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2025Review
- The Role of Kidney Function in Predicting COVID-19 Severity and Clinical Outcomes: A Retrospective Analysis.Infectious disease reports · 2025Article
- Evaluation of Function and Biochemical Parameters of Platelet Concentrates (PCs) Prepared From Blood Donors With a History of COVID-19 During the Platelet Storage.Journal of clinical laboratory analysis · 2025Article
- Aging-associated changes in immunological parameters: Implications for COVID-19 immune response in the elderly.Physiological reports · 2025Review
- Efficient and scalable construction of clinical variable networks for complex diseases with RAMEN.Cell reports methods · 2025Article
- Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health.GeroScience · 2025Review
- COVID-19: a vascular nightmare unfolding.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
COVID-19 is characterized by dysregulated thrombosis and coagulation that can increase mortality in patients. Platelets are fast responders to pathogen presence, alerting the surrounding immune cells and contributing to thrombosis and intravascular coagulation. The SARS-CoV-2 genome has been found in platelets from patients with COVID-19, and its coverage varies according to the method of detection, suggesting direct interaction of the virus with these cells. Antibodies against Spike and Nucleocapsid have confirmed this platelet-viral interaction. This review discusses the immune, prothrombotic, and procoagulant characteristics of platelets observed in patients with COVID-19. We outline the direct and indirect interaction of platelets with SARS-CoV-2, the contribution of the virus to programmed cell death pathway activation in platelets and the consequent extracellular vesicle release. We discuss platelet activation and immunothrombosis in patients with COVID-19, the effect of Spike on platelets, and possible activation of platelets by classical platelet activation triggers as well as contribution of platelets to complement activation. As COVID-19-mediated thrombosis and coagulation are still not well understood in vivo, we discuss available murine models and mouse adaptable strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.